Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- ViiV’s HIV Drug Juluca to Join NHI Price List on Dec. 12
December 5, 2018
- Survey Suggests 5% Regular Price Cut in 2019, 2% Tax Hike to Offset Reduction
December 5, 2018
- MHLW Panel OKs Amgen Astellas’ Romosozumab, but ADHD Drug Vyvanse Put on Hold
December 4, 2018
- Keytruda’s Tumor-Agnostic Use, Gilead’s Epclusa, Wider Hemlibra Label Now in Line for Approval by Year-End
November 30, 2018
- Govt Deregulation Team Calls for Review of Info Required in Micatrio Reimbursement Claims
November 30, 2018
- LDP Lawmakers Push for Expansion of R&D Tax Credit
November 30, 2018
- AMED Study Group Drafting Japan’s 1st Guidelines for Development of Recombinant Virus Vaccines
November 29, 2018
- MHLW Orders Label Revisions for Mitsubishi Tanabe’s Zione; “Anaphylaxis” to Be Added to Adverse Reactions
November 28, 2018
- Certain Amount of Production Hikes of Measles-Rubella Vaccine in Japan Possible: Health Minister
November 28, 2018
- Pfizer Skips Listing of Herceptin Biosimilar, Daiichi Sankyo Goes Ahead
November 27, 2018
- MHLW Proposes Introduction of Administrative Fines for Improperly Earned Revenues
November 27, 2018
- MHLW Panel Recommends Conditional Approval for Nipro’s Stem Cell Product for Spinal Cord Injury
November 26, 2018
- MHLW Eyes Drastic Change to Cost Effective Analysis Flow, Enhanced Discussions Upfront
November 22, 2018
- MHLW Proposes Quarterly Product Selections, Price Tweaks for CEA Scheme: Chuikyo
November 22, 2018
- MOF Panel Urges Govt to Use Economic Evaluations for Reimbursement Decisions: FY2019 Budget Recommendation
November 21, 2018
- Amgen Astellas’s Osteoporosis Med Romosozumab Up for MHLW Panel Review on Dec. 3
November 20, 2018
- Keytruda’s MSI-H Cancer Use Up for MHLW Panel Review Nov. 29; Wider Hemlibra Indication, 1st Line Tecentriq Also on Agenda
November 16, 2018
- Chuikyo Agrees on October 2019 Drug Price Revision for Tax Hike, but Final Call Is Up to Govt
November 15, 2018
- MHLW Revises Imfinzi’s Optimal Use Guidelines for NSCLC, Calling for PD-L1 Expression Test
November 15, 2018
- Novo’s Ozempic Skips Listing for 3rd Time 8 Months after Approval
November 14, 2018
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…